By: Benzinga
January 03, 2013 at 08:26 AM EST
UPDATE: Citigroup Upgrades Acorda Therapeutics to Buy on Limited Downside, Catalysts
Citigroup raised its rating on Acorda Therapeutics (NASDAQ: ACOR ) from Neutral to Buy and raised its price target from $28 to $33. Citigroup said, "We expect Ampyra to continue to grow fueled by modest market share gains and price increases. We project a 10% price increase in Q1:13
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here